atagabalin
≈ 1 min read
Names in other languages
- Englishatagabalin
- igAtagabalin
- shAtagabalin
- СрпскиAtagabalin
- 中文PD-200,390
- 日本語アタガバリン
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
Atagabalin ( , ; developmental code name PD-0200390) is a drug developed by Pfizer and related to gabapentin, which similarly binds to the α 2 δ calcium channels (1 and 2). It was under development as a treatment for insomnia, but was discontinued following unsatisfactory trial results. The drug reached phase 2 clinical trials for this indication prior to the discontinuation of its development.
Atagabalin ( , ; developmental code name PD-0200390) is a drug developed by Pfizer and related to gabapentin, which similarly binds to the α 2 δ calcium channels (1 and 2). It was under development as a treatment for insomnia, but was discontinued following unsatisfactory trial results. The drug reached phase 2 clinical trials for this indication prior to the discontinuation of its development.
See also
List of investigational insomnia drugs 4-Methylpregabalin Gabapentin enacarbil PD-217,014 PD-0299685
References
Text derived from https://en.wikipedia.org/w/index.php?oldid=1377083041 under CC BY-SA 4.0; modifications have been made.